Prediction of response to salvage radiation therapy in patients with prostrate cancer recurrence after radical prostatectomy

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1030-1039

  Leventis, A K ^a   Shariat, S F ^a   Kattan, M W ^a   Butler, E B ^a   Wheeler, T M ^a   Slawin, K M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY;

EID: 0035865443     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1030     Document Type: Article

References (55)

1. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
2. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
3. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
4. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy
5. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins
6. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy
7. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy
8. Positron emission tomography in urological oncology
9. Radioimmunoscintigraphy with 1n-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
10. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures alter radical prostatectomy
11. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
12. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
13. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
14. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy
15. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy
16. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy
17. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy
18. Fresh tissue harvest for research from prostatectomy specimens
19. Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
20. Consensus statement: Guidelines for PSA following radiation therapy
21. Natural history of progression after PSA elevation following radical prostatectomy
22. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1251 implantation
23. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy
24. Potential benefit of improved local tumor control in patients with prostate carcinoma
25. Modeling the development of metastases from primary and locally recurrent tumors: Comparison with a clinical data base for prostatic cancer
26. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy
27. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer
28. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level
29. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy
30. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy
31. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer
32. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy
33. Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy
34. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen
35. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation
36. Predicting the need for adjuvant systemic therapy in patients receiving postprostatectomy irradiation
37. Prognostic factors of organ confined prostate cancer with level 2 capsular invasion after radical prostatectomy
38. Prostate specific antigen and local recurrence after radical prostatectomy
39. Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer
40. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
41. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels
42. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy: A long term follow-up
43. The effect of dose on local control of prostate cancer
44. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma
45. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy
46. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer
47. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: Implications for patterns of failure and definition of cure
48. Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time
49. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer
50. The role of external beam radiation therapy after prostatectomy for prostate cancer
51. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: Ten-year update
52. Adjuvant radiotherapy in patients with pathologic stage C (pT3N0) adenocarcinoma of the prostate
53. Positive margins: Is adjunctive radiation therapy indicated?
54. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: Analysis of freedom from PSA failure
55. Prostate specific antigen and local recurrence after radical prostatectomy